Pliant Therapeutics (PLRX) Accumulated Expenses (2019 - 2026)

Pliant Therapeutics (PLRX) has 8 years of Accumulated Expenses data on file, last reported at $4.1 million in Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $4.1 million, down 44.23% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.1 million (down 44.23% YoY), and the FY2025 annual result was $9.6 million, down 22.01% from the prior year.
• Accumulated Expenses eased to $4.1 million in Q1 2026 per PLRX's latest filing, from $9.6 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $20.3 million in Q3 2022 and troughed at $4.1 million in Q1 2026.
• A 5-year average of $9.5 million and a median of $8.3 million in 2023 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2022 and 2023: Accumulated Expenses jumped 112.97% in 2022, then tumbled 61.13% in 2023.
• A 5-year view of Accumulated Expenses shows it stood at $8.7 million in 2022, then rose by 18.03% to $10.2 million in 2023, then climbed by 20.88% to $12.4 million in 2024, then slipped by 22.01% to $9.6 million in 2025, then sank by 57.0% to $4.1 million in 2026.
• Business Quant data shows PLRX's Accumulated Expenses at $4.1 million in Q1 2026, $9.6 million in Q4 2025, and $8.2 million in Q3 2025.